Clinical Trial Update: Oral ONC201 in Adult Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of oral ONC201 in adult recurrent glioblastoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Ganglia Glioma
• Diffuse Midline Glioma
• Glioblastoma
• H3 K27m Glioma
• Infratentorial Glioma
• Thalamic Glioma

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Glioblastoma, Diffuse Midline Glioma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-24